Blowing the Whistle at the FDA, Jan 2001, exposing Dearborn and how OspA causes immunosuppression rather than, "was a vaccine."
 


01 Oct 2017

Home


File List, RICO

1988 Steere says Lyme is like a B cell leukemia

Assoc Blogs-n-Webs:
TruthCures.org
badlymeattitude.com/
immune2lies.com/
researchfraud.com/
may12.org
meadvocacy.org/
truthbetoldx81
lymecryme
CrymeDiseaseNorway
crymedisease
theothersideofthestretcher
rjspiritualityandtuth
LymeTruthSite

JC-LilnkedIn
KD-Linkedin.com
LD-LinkedIn
JC-academia.edu

KD-academia.edu

 


CDC "SPIDER"

Fungal Exosomes Inhibit Apoptosis

IDSA: "Vaccines serve the mfgs, not their victims"

RICO_filed_USDOJ

BlumenthalAntiTrust Lawsuit

Exosomes, Blebs

Spirochetal_Dementia


PDFs
CDC Admits Fraud, 2016
Dattwyler, 1988
Golightly, 1988
Dressler, 1994
BarbourFish, 1993
Dearborn, 1994
BarbourFishpdf.pdf
 

Pathogenic Fungi

Bush's warcrimes, Oct 2000

Trainer

170708

 



On this page is a snippet from a report by Yale's Erol Fikrig in which he reveals that OspA cannot be used as a vaccine - it is a relapsing fever organism, the nature of the relapse is antigenic variation, so antibodies made are soon rendered useless, as the bugs produces a whole new slew of outer surface antigens....

Additionally, the full text of the CDC officer Alan Barbour reporting that OspA can not be used as a vaccine because it, OspA, too, undergoes antigenic variation,
HERE.  [Alan Barbour holds the patent for the Pasteur Connaught (now Aventis) ImmuLyme OspA vaccine that also failed and was falsely reported as safe and effective by Lenny Sigal, et al in 1998.]

One would have to be a STUPID male to ever think there could be a vaccine for Relapsing Fever.  "Selection pressure" is the term that means "antibodies against specific antigens of Borreliae are rendered useless due to antigenic variation, which means there can never be a vaccine for relapsing fever borreliosis or Lyme borreliosis."  (See also the McSweegan letter to Barry Goldwater and how Sweeg had no idea what "relapsing fever" even meant, or that his "cloned ehrlichial ligands" also undergo selection pressure and cannot ever be vaccines. What a complete idiot...)

070830;0520 It was a very stupid idea- a vaccine for Relapsing Fever.  The nature of the relapse is the exact reason there can be no vaccine.

Yale's Erol Fikrig publishes above that antibodies (created by either human infection or vaccine) create "selection pressure."  That's the newer term for "antibodies causing the surface antigen changes that cause the relapse which is the reason there can never be a vaccine for Relapsing Fever." 

Here is the link to that full text report: http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=173206&blobtype=pdf

 

You can see below that CDC "officer" Alan Barbour publishes the exact same thing in 1992, in the next abstract.  He uses monoclonal antibodies to "select for variants" all the time.  He also reports that OspA and B do true antigenic variation.

 
: J Exp Med. 1992 Sep 1;176(3):799-809.Links
Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization.

Department of Microbiology, University of Texas Health Science Center, San Antonio 78284.

We used polyclonal antisera and monoclonal antibodies (mAbs) to inhibit the growth of clonal populations of two strains of Borrelia burgdorferi, the Lyme disease agent, and thereby select for antibody-resistant mutants. mAbs were directed at the outer membrane proteins, OspA or OspB. Mutants resistant to the growth-inhibiting properties of the antibodies were present in the populations at frequencies ranging from 10(-5) to 10(-2). The several escape variants that were examined were of four classes. Class I mutants were resistant to all mAbs; they lacked OspA and OspB and the linear plasmid that encodes them. Two other proteins were expressed in larger amounts in class I mutants; mAbs to these proteins inhibited the mutant but not the wild-type cells. Class II mutants were resistant to some but not all mAbs; they had truncated OspA and/or OspB proteins. Class III mutants were resistant only to the selecting mAb; they had full-length Osp proteins that were not bound by the selecting antibody in Western blots. In two class III mutants resistant to different anti-OspA mAbs, missense mutations were demonstrated in the ospA genes. Class IV mutants were likewise resistant only to selecting antibody, but in this case the selecting antibody still bound in Western blots. PMID: 1339462 [PubMed - indexed for MEDLINE]

 

This means these guys all knew all along there could never be a vaccine for borrreliosis.   Alan Barbour owns the patent for ImmuLyme or the other OspA vaccine. 

Go here for lots of patent data and information about how OspA causes Immune-Suppression-related illnesses.  It's at the bottom of that web page.